AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15425
Abstract: AZD8233 is a proprotein convertase subtilisin/kexin type 9 (PCSK9) antisense oligonucleotide under development for treatment of hypercholesterolaemia. A prespecified concentrationâQT analysis was performed based on data from a single ascending dose study that was prospectively… read more here.
Keywords: antisense oligonucleotide; targeting pcsk9; azd8233 antisense; azd8233 ... See more keywords